List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8736167/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mortality among inpatients with bipolar disorders and COVID-19: a propensity score matching analysis in a national French cohort study. Psychological Medicine, 2023, 53, 1979-1988.	2.7	5
2	Barriers in psychiatrists' mind to active smoking cessation promotion in severe psychiatric disorders. L'Encephale, 2023, 49, 21-26.	0.3	0
3	The puzzle of quality of life in schizophrenia: putting the pieces together with the FACE-SZ cohort. Psychological Medicine, 2022, 52, 1501-1508.	2.7	7
4	Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study. Schizophrenia Bulletin, 2022, 48, 382-394.	2.3	7
5	The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry. L'Encephale, 2022, 48, 102-104.	0.3	5
6	Which antipsychotics should be chosen for the treatment of schizo-obsessive disorder?. L'Encephale, 2022, 48, 349-350.	0.3	1
7	Anxiety and depression in young physicians: Prevalence and associated factors. The MESSIAEN national study. L'Encephale, 2022, 48, 26-30.	0.3	13
8	Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 905-912.	3.3	6
9	Handedness in bipolar disorders is associated with specific neurodevelopmental features: results of the BD-FACE cohort. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 827-838.	1.8	3
10	Risk factors for burnout and depression in healthcare workers: The national AMADEUS study protocol. L'Encephale, 2022, 48, 247-253.	0.3	9
11	Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110479.	2.5	7
12	The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project. Journal of Clinical Medicine, 2022, 11, 743.	1.0	3
13	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 703-714.	1.3	2
14	Psychotic symptomatology and medication adherence in patients with schizophrenia: The mediating effect of awareness of mental disorder. Schizophrenia Research, 2022, 241, 110-112.	1.1	0
15	Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1379-1384.	1.8	2
16	Work environment and mental health in nurse assistants, nurses and health executives: Results from the AMADEUS study. Journal of Nursing Management, 2022, 30, 2268-2277.	1.4	8
17	Development and Calibration of the PREMIUM Item Bank for Measuring Respect and Dignity for Patients with Severe Mental Illness. Journal of Clinical Medicine, 2022, 11, 1644.	1.0	3
18	ADHD and addictive behavior in crack-cocaine users. L'Encephale, 2022, , .	0.3	0

#	Article	IF	CITATIONS
19	Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort. Brain, Behavior, & Immunity - Health, 2022, 22, 100436.	1.3	2
20	Barriers and opportunities for the continuous training of healthcare professionals in the post-Covid era. L'Encephale, 2022, 48, 117.	0.3	2
21	Intensive end-of-life care in acute leukemia from a French national hospital database study (2017–2018). BMC Palliative Care, 2022, 21, 45.	0.8	0
22	Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort. Cognitive Neuropsychiatry, 2022, 27, 49-68.	0.7	2
23	Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort. World Journal of Biological Psychiatry, 2022, 23, 525-536.	1.3	5
24	Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ). European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	1.8	2
25	Septic shock: incidence, mortality and hospital readmission rates in French intensive care units from 2014 to 2018. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101082.	0.6	13
26	ADHD prevalence in patients with hypersexuality and paraphilic disorders: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1413-1420.	1.8	7
27	Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. Molecular Psychiatry, 2022, 27, 4172-4180.	4.1	52
28	Schizophrenia pregnancies should be given greater health priority in the global health agenda: results from a large-scale meta-analysis of 43,611 deliveries of women with schizophrenia and 40,948,272 controls. Molecular Psychiatry, 2022, 27, 3294-3305.	4.1	8
29	Hazardous drinking is associated with hypnotic consumption in medical students in the BOURBON nationwide study: psychological factors explored. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 883-889.	1.8	3
30	Prevalence and associated factors of cannabis consumption in medical students: the BOURBON nationwide study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 857-864.	1.8	3
31	Repeated bullying at the workplace in medical students and young doctors: the MESSIAEN national study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1123-1131.	1.8	7
32	Disparities in Intensive Care Unit Admission and Mortality Among Patients With Schizophrenia and COVID-19: A National Cohort Study. Schizophrenia Bulletin, 2021, 47, 624-634.	2.3	72
33	Unplanned readmission and survival after video-assisted thoracic surgery and open thoracotomy in patients with non-small-cell lung cancer: a 12-month nationwide cohort study. European Journal of Cardio-thoracic Surgery, 2021, 59, 987-995.	0.6	10
34	Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin, 2021, 47, 298-308.	2.3	45
35	Depressive symptoms and chronic peripheral inflammation are associated with impaired functional remission in schizophrenia independently of psychotic remission Journal of Affective Disorders, 2021, 280, 267-271.	2.0	7
36	A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France. Journal of Market Access & Health Policy, 2021, 9, 1885789.	0.8	11

#	Article	IF	CITATIONS
37	The association between initial motivation for medical studies and specialty choice in young French physicians. L'Encephale, 2021, 47, 1-3.	0.3	1
38	You get psychotropic drugs, so you don't need vaccination against Covid 19?. L'Encephale, 2021, 47, 87-88.	0.3	1
39	Increased in-hospital mortality from COVID-19 in patients with schizophrenia. L'Encephale, 2021, 47, 89-95.	0.3	33
40	End of life breast cancer care in women with severe mental illnesses. Scientific Reports, 2021, 11, 10167.	1.6	8
41	Outcome prediction with a social cognitive battery: a multicenter longitudinal study. NPJ Schizophrenia, 2021, 7, 30.	2.0	4
42	Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries. JAMA Psychiatry, 2021, 78, 1208.	6.0	155
43	Cross-Cultural Adaptation and Validation of the Quality of Life Questionnaire for Caregivers of Patients with Schizophrenia (S-CGQoL) in Latin America. L'Encephale, 2021, 47, 291-298.	0.3	Ο
44	Psychonutritional intervention for autism spectrum disorders. L'Encephale, 2021, 47, 289-290.	0.3	0
45	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110275.	2.5	3
46	Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: Findings from the FACE-SZ Cohort. Psychiatry Research, 2021, 303, 114044.	1.7	5
47	Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study. Lancet Regional Health - Europe, The, 2021, 10, 100209.	3.0	17
48	Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110335.	2.5	3
49	Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Schizophrenia Bulletin Open, 2021, 2, sgab012.	0.9	20
50	Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis. Nutrients, 2021, 13, 3947.	1.7	35
51	Malformations and pregnancy with schizophrenia – Authors' reply. Lancet Regional Health - Europe, The, 2021, 11, 100257.	3.0	1
52	Relationships between social stigma, stigma experience and self-stigma and impaired quality of life in schizophrenia across three Latin-American countries. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 513-520.	1.8	17
53	Trauma-related mortality of patients with severe psychiatric disorders: population-based study from the French national hospital database. British Journal of Psychiatry, 2020, 217, 568-574.	1.7	7
54	Abnormal C-reactive protein blood levels as a specific biomarker of major depression and non-remission under antidepressants in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 97, 109800.	2.5	8

#	Article	IF	CITATIONS
55	Sexual dysfunctions in schizophrenia: Beyond antipsychotics. A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 98, 109804.	2.5	31
56	Mise en place et évaluation de séances d'éthique appliquée dans un service de psychiatrie génÃ@ France. Annales Medico-Psychologiques, 2020, 178, 884-890.	Orale en	2
57	Assessing metacognitive and help-seeking strategies in schizophrenia: design and psychometric validation of the Versailles Metacognitive Strategies Evaluation Questionnaire. Clinical Rehabilitation, 2020, 34, 263-275.	1.0	3
58	Recurrent major depressive disorder's impact on end-of-life care of cancer: A nationwide study. Journal of Affective Disorders, 2020, 263, 326-335.	2.0	8
59	Improving diet for psychiatric patientsÂ: High potential benefits and evidence for safety. Journal of Affective Disorders, 2020, 265, 567-569.	2.0	14
60	Use of artificial nutrition near the end of life: Results from a French national populationâ€based study of hospitalized cancer patients. Cancer Medicine, 2020, 9, 530-540.	1.3	13
61	<p>Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures</p> . Patient Preference and Adherence, 2020, Volume 14, 2147-2161.	0.8	32
62	Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study. European Archives of Psychiatry and Clinical Neuroscience, 2020, 271, 1571-1578.	1.8	8
63	<p>Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia</p> . Patient Preference and Adherence, 2020, Volume 14, 1595-1604.	0.8	8
64	End-of-Life Care Among Patients With Bipolar Disorder and Cancer: A Nationwide Cohort Study. Psychosomatic Medicine, 2020, 82, 722-732.	1.3	7
65	Machine-learning prediction of unplanned 30-day rehospitalization using the French hospital medico-administrative database. Medicine (United States), 2020, 99, e22361.	0.4	7
66	Effectiveness of a housing support team intervention with a recovery-oriented approach on hospital and emergency department use by homeless people with severe mental illness: a randomised controlled trial. Epidemiology and Psychiatric Sciences, 2020, 29, e169.	1.8	40
67	Sexual harassment exposure and impaired mental health in medical students. The MESSIAEN national study. Journal of Affective Disorders, 2020, 274, 276-281.	2.0	9
68	Sexual-orientation based discrimination is associated with anxiety and depression in young physicians. A national study Journal of Affective Disorders, 2020, 274, 964-968.	2.0	11
69	Confirmations, advances and recommendations for the daily care of schizophrenia based on the French national FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109927.	2.5	11
70	The role of neighbourhood socioeconomic status in large for gestational age. PLoS ONE, 2020, 15, e0233416.	1.1	12
71	Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI). Cell Death and Disease, 2020, 11, 502.	2.7	16
72	Early and very earlyâ€onset schizophrenia compared with adultâ€onset schizophrenia: French FACEâ€SZ database. Brain and Behavior, 2020, 10, e01495.	1.0	38

#	Article	IF	CITATIONS
73	First-year French medical students consume antidepressants and anxiolytics while second-years consume non-medical drugs Journal of Affective Disorders, 2020, 265, 71-76.	2.0	7
74	Brain PET metabolic substrate of TMS response in pharmaco-resistant depression. Brain Stimulation, 2020, 13, 683-685.	0.7	6
75	The Role of Inflammation in the Treatment of Schizophrenia. Frontiers in Psychiatry, 2020, 11, 160.	1.3	84
76	Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort Journal of Affective Disorders, 2020, 274, 617-623.	2.0	11
77	Improving the treatment and remission of major depression in homeless people with severe mental illness: The multicentric French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 99, 109877.	2.5	7
78	How to treat inflammatory schizophrenia?. L'Encephale, 2020, 46, 411-413.	0.3	0
79	Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder. EJNMMI Research, 2020, 10, 121.	1.1	7
80	Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 879-886.	1.8	12
81	The need to improve detection and treatment of physical pain of homeless people with schizophrenia and bipolar disorders. Results from the French Housing First Study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 175-180.	2.5	9
82	Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 985-992.	1.8	39
83	A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort. Schizophrenia Research, 2019, 204, 38-45.	1.1	7
84	Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale. Clinical Rehabilitation, 2019, 33, 113-119.	1.0	3
85	Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort. Journal of Clinical Medicine, 2019, 8, 1196.	1.0	9
86	Microbiote et dépressionÂ: une piste thérapeutique prometteuse. Annales Medico-Psychologiques, 2019, 177, 695-697.	0.2	0
87	End-of-life care among patients with schizophrenia and cancer: a population-based cohort study from the French national hospital database. Lancet Public Health, The, 2019, 4, e583-e591.	4.7	56
88	Confirmation of a Two-Factor Solution to the Questionnaire of Cognitive and Affective Empathy in a French Population of Patients With Schizophrenia Spectrum Disorders. Frontiers in Psychiatry, 2019, 10, 751.	1.3	6
89	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational Psychiatry, 2019, 9, 20.	2.4	52
90	Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109654.	2.5	13

#	Article	IF	CITATIONS
91	Anxiolytic consumption is associated with tobacco smoking and severe nicotine dependence. Results from the national French medical students (BOURBON) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109645.	2.5	19
92	Driving us mad: the association of <i>Toxoplasma gondii</i> with suicide attempts and traffic accidents – a systematic review and meta-analysis. Psychological Medicine, 2019, 49, 1608-1623.	2.7	47
93	Relationship between childhood trauma and level of insight in schizophrenia: A path-analysis in the national FACE-SZ dataset. Schizophrenia Research, 2019, 208, 90-96.	1.1	10
94	Highâ€intensity endâ€ofâ€life care among children, adolescents, and young adults with cancer who die in the hospital: A populationâ€based study from the French national hospital database. Cancer, 2019, 125, 2300-2308.	2.0	29
95	Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 599-610.	1.8	14
96	<p>The Patient-Reported Experience Measure for Improving qUality of care in Mental health (PREMIUM) project in France: study protocol for the development and implementation strategy</p> . Patient Preference and Adherence, 2019, Volume 13, 165-177.	0.8	26
97	The Latin American version of the internalized stigma of mental illness scale (LA-ISMI): a multicentric validation study from three Latin American countries. Health and Quality of Life Outcomes, 2019, 17, 175.	1.0	7
98	Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 84-89.	2.5	13
99	Burnout in French physicians: A systematic review and meta-analysis. Journal of Affective Disorders, 2019, 246, 132-147.	2.0	96
100	Machine learning for predicting psychotic relapse at 2†years in schizophrenia in the national FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 8-18.	2.5	27
101	Psychiatric and psychological follow-up of undergraduate and postgraduate medical students: Prevalence and associated factors. Results from the national BOURBON study. Psychiatry Research, 2019, 272, 425-430.	1.7	22
102	Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort. Journal of Affective Disorders, 2019, 245, 468-474.	2.0	7
103	Illness and drug modifiable factors associated with violent behavior in homeless people with severe mental illness: results from the French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 92-96.	2.5	12
104	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 226-234.	2.5	12
105	Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 449-457.	1.8	22
106	Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics. Journal of Clinical Psychiatry, 2019, 80, .	1.1	23
107	Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 62-68.	2.5	14
108	Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset. European Neuropsychopharmacology, 2018, 28, 24-36.	0.3	26

#	Article	IF	CITATIONS
109	Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 17-26.	1.8	23
110	Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort. Schizophrenia Research, 2018, 195, 357-365.	1.1	9
111	Risk factors for increased duration of untreated psychosis. Results from the FACE-SZ dataset. Schizophrenia Research, 2018, 195, 529-533.	1.1	15
112	Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 541-553.	1.8	29
113	Victimization and posttraumatic stress disorder in homeless women with mental illness are associated with depression, suicide, and quality of life. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2269-2279.	1.0	38
114	Le microbiote intestinal gouverne-t-il notre cerveauÂ?. Annales Medico-Psychologiques, 2018, 176, 824-830.	0.2	0
115	Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort Psychiatry Research, 2018, 270, 104-110.	1.7	14
116	Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort. Schizophrenia Research, 2018, 201, 373-380.	1.1	27
117	Gender differences in schizophrenia: A multicentric study from three Latin-America countries. Psychiatry Research, 2018, 266, 65-71.	1.7	11
118	Psychiatric disability as mediator of the neurocognition-functioning link in schizophrenia spectrum disorders: SEM analysis using the Evaluation of Cognitive Processes involved in Disability in Schizophrenia (ECPDS) scale. Schizophrenia Research, 2018, 201, 196-203.	1.1	4
119	Venus and Mars on the benches of the faculty: Influence of gender on mental health and behavior of medical students. Results from the BOURBON national study. Journal of Affective Disorders, 2018, 239, 146-151.	2.0	22
120	C-Reactive Protein as a Peripheral Biomarker in Schizophrenia. An Updated Systematic Review. Frontiers in Psychiatry, 2018, 9, 392.	1.3	53
121	Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. British Journal of Psychiatry, 2018, 213, 464-470.	1.7	35
122	Psychiatry: A discipline at specific risk of mental health issues and addictive behavior? Results from the national BOURBON study. Journal of Affective Disorders, 2018, 238, 534-538.	2.0	19
123	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia. Journal of Clinical Psychiatry, 2018, 79, .	1.1	21
124	L'immunopsychiatrie existe-t-elle ?. Phytotherapie, 2018, 16, 347-352.	0.1	0
125	Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. Schizophrenia Research, 2017, 185, 173-181.	1.1	48
126	Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 465-472.	1.8	18

#	Article	IF	CITATIONS
127	Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort. Psychiatry Research, 2017, 254, 218-223.	1.7	7
128	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 567-577.	1.8	21
129	Would I take antipsychotics, if I had psychotic symptoms? Examining determinants of the decision to take antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 155-163.	2.5	8
130	Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 1113-1122.	1.6	7
131	Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia. Results from the Face-SZ dataset. European Psychiatry, 2017, 41, s831-s831.	0.1	0
132	Current Smoking in Real World Schizophrenia: Relationship to Psychopathology and Clinical Characteristics. Results from the FACE Dataset. European Psychiatry, 2017, 41, S98-S98.	0.1	0
133	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. Journal of Psychiatric Research, 2017, 94, 62-69.	1.5	14
134	Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 332-339.	2.5	31
135	Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophrenia Research, 2017, 182, 84-89.	1.1	41
136	C-reactive protein as a differential biomarker of bipolar II depression versus major depressive disorder. World Journal of Biological Psychiatry, 2017, 18, 71-72.	1.3	5
137	Birth by cesarean section and schizophrenia: results from the multicenter FACE-SZ data-set. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 587-594.	1.8	17
138	Psychometric properties of the Ruminative Response Scale-short form in a clinical sample of patients with major depressive disorder. Patient Preference and Adherence, 2017, Volume 11, 929-937.	0.8	42
139	Medication nonadherence among South American patients with schizophrenia. Patient Preference and Adherence, 2017, Volume 11, 1737-1744.	0.8	10
140	Disparities in suicide mortality trends between United States of America and 25 European countries: retrospective analysis of WHO mortality database. Scientific Reports, 2016, 6, 20256.	1.6	27
141	Dealing with current tobacco smoking in real world schizophrenia. Results from the Face-Schizophrenia dataset. European Neuropsychopharmacology, 2016, 26, S578-S579.	0.3	0
142	Cognitive impairment associated with benzodiazepine long-term administration in schizophrenia, results from the multicentre FACE-SZ dataset. European Neuropsychopharmacology, 2016, 26, S326.	0.3	0
143	Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia, results from the multicentric FACE-SZ dataset. European Neuropsychopharmacology, 2016, 26, S499.	0.3	0
144	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ dataset. European Psychiatry, 2016, 33, S98-S98.	0.1	0

#	Article	IF	CITATIONS
145	Medication and aggressiveness in "real world―schizophrenia: current issues and perspectives. Psychopharmacology, 2016, 233, 2421-2423.	1.5	2
146	Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia. Schizophrenia Research, 2016, 175, 161-167.	1.1	26
147	Potentially inappropriate psychotropic prescription at discharge is associated with lower functioning in the elderly psychiatric inpatients. A cross-sectional study. Psychopharmacology, 2016, 233, 2549-2558.	1.5	14
148	Motives And Behaviors of Medical Students (mis)using Prescription Stimulants. European Psychiatry, 2016, 33, S448-S448.	0.1	0
149	The Prevalence of Mental Disorders Among Children and Adolescents in the Child Welfare System. Medicine (United States), 2016, 95, e2622.	0.4	194
150	Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. Schizophrenia Bulletin, 2016, 42, 1290-1302.	2.3	82
151	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. European Psychiatry, 2016, 33, s242-s243.	0.1	0
152	WAIS-IV Seven-Subtest Short Form: Validity and Clinical Use in Schizophrenia. Archives of Clinical Neuropsychology, 2016, 31, 915-925.	0.3	17
153	Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia. Schizophrenia Research, 2016, 178, 1-5.	1.1	9
154	Violent behavior and aggression in schizophrenia: Prevalence and risk factors. A multicentric study from three Latin-America countries. Schizophrenia Research, 2016, 178, 23-28.	1.1	31
155	Interleukinâ€1 βâ€ŧargeted treatment strategies in inflammatory depression: toward personalized care. Acta Psychiatrica Scandinavica, 2016, 134, 469-484.	2.2	44
156	A Bayesian framework systematic review and meta-analysis of anesthetic agents effectiveness/tolerability profile in electroconvulsive therapy for major depression. Scientific Reports, 2016, 6, 19847.	1.6	29
157	Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: Results from the French Housing First experience. Scientific Reports, 2016, 6, 31598.	1.6	19
158	(Mis)use of prescribed stimulants in the medical student community: Motives and behaviors. A population-based cross-sectional study. European Neuropsychopharmacology, 2016, 26, S348-S349.	0.3	2
159	Akathisia: Prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the multi-center FACE-SZ Dataset. European Psychiatry, 2016, 33, S96-S97.	0.1	1
160	Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks. Psychopharmacology, 2016, 233, 933-935.	1.5	6
161	Birth by cesarean section and schizophrenia. Results from the multi-center FACE-SZ dataset. European Psychiatry, 2016, 33, S98-S98.	0.1	0
162	(Mis)use of Prescribed Stimulants in the Medical Student Community. Medicine (United States), 2016, 95, e3366.	0.4	50

#	Article	IF	CITATIONS
163	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophrenia Research, 2016, 171, 27-34.	1.1	61
164	Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. Journal of Affective Disorders, 2016, 191, 209-215.	2.0	37
165	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. Psychopharmacology, 2016, 233, 571-578.	1.5	21
166	Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence. Journal of Clinical Psychiatry, 2016, 77, e1130-e1136.	1.1	31
167	Anti-inflammatory drugs add-on therapy in major psychiatric disorders. European Psychiatry, 2015, 30, S24-S25.	0.1	Ο
168	Abnormal C-reactive protein (CRP) levels in schizophrenia and schizoaffective disorders. Results from the FACE-SZ dataset. European Psychiatry, 2015, 30, S112-S112.	0.1	4
169	Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset. European Psychiatry, 2015, 30, S153-S154.	0.1	Ο
170	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. Schizophrenia Research, 2015, 168, 388-394.	1.1	57
171	Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophrenia Research, 2015, 169, 255-261.	1.1	34
172	Prevalence and Smoking Behavior Characteristics of Nonselected Smokers With Childhood and/or Adult Self-Reported ADHD Symptoms in a Smoking-Cessation Program. Journal of Attention Disorders, 2015, 19, 293-300.	1.5	18
173	Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: A cross-sectional study. Journal of Psychiatric Research, 2015, 63, 58-64.	1.5	39
174	Mood disorders are associated with a more severe hypovitaminosis D than schizophrenia. Psychiatry Research, 2015, 229, 613-616.	1.7	30
175	Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. Psychiatry Research, 2015, 229, 12-20.	1.7	36
176	A National Network of Schizophrenia Expert Centres: an Innovative Tool to Bridge the Research-Practice Gap. European Psychiatry, 2015, 30, 728-735.	0.1	82
177	Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophrenia Research, 2015, 165, 94-96.	1.1	24
178	Beyond the association. <i><scp>T</scp>oxoplasma gondii</i> in schizophrenia, bipolar disorder, and addiction: systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2015, 132, 161-179.	2.2	346
179	The Promise of Biological Markers for Treatment Response in First-Episode Psychosis: A Systematic Review. Schizophrenia Bulletin, 2015, 41, 559-573.	2.3	93
180	Google Trends®: Ready for real-time suicide prevention or just a Zeta-Jones effect? An exploratory study. Psychiatry Research, 2015, 228, 913-917.	1.7	34

#	Article	IF	CITATIONS
181	A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia. Translational Psychiatry, 2015, 5, e608-e608.	2.4	22
182	The World Health Organization (WHO) dataset for guiding suicide prevention policies: A 3-decade French national survey. Journal of Affective Disorders, 2015, 188, 232-238.	2.0	6
183	Ketamine vs other anesthetic agents for electroconvulsive therapy (ECT) in major depression. Journal of Psychiatric Research, 2015, 68, 226-227.	1.5	0
184	Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ dataset. European Psychiatry, 2015, 30, S130-S130.	0.1	2
185	The "psychomicrobiotic†Targeting microbiota in major psychiatric disorders: A systematic review. Pathologie Et Biologie, 2015, 63, 35-42.	2.2	158
186	Ketamine's effectiveness in unipolar versus bipolar depression. Psychopharmacology, 2014, 231, 4417-4418.	1.5	4
187	Do the treasures of â€`big data' combined with behavioural intervention therapies contain the key to the mystery of large psychiatric issues?. Acta Psychiatrica Scandinavica, 2014, 130, 406-407.	2.2	6
188	Effectiveness and tolerance of antiâ€inflammatory drugs' addâ€on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica, 2014, 129, 163-179.	2.2	140
189	EEG neurofeedback treatments in children with ADHD: an updated meta-analysis of randomized controlled trials. Frontiers in Human Neuroscience, 2014, 8, 906.	1.0	115
190	Aspirin for prevention of cardiovascular events in bipolar disorders. Psychiatry Research, 2014, 219, 238-239.	1.7	1
191	Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 179-183.	1.8	46
192	Recently discovered properties of aspirin may be doubly helpful in bipolar disorders. Medical Hypotheses, 2014, 82, 640-641.	0.8	3
193	Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 651-660.	1.8	440
194	Inflammation in psychiatric disorders. European Psychiatry, 2014, 29, 551-552.	0.1	4
195	Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology, 2014, 231, 3663-3676.	1.5	278
196	D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology, 2014, 231, 3765-3770.	1.5	39
197	Smoking behavior characteristics of non-selected smokers with childhood attention-deficit/hyperactivity disorder (AD/HD) history: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 379-389.	1.8	7
198	Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. Psychiatry Research, 2014, 216, 286-287.	1.7	4

#	Article	IF	CITATIONS
199	The covariation of independent and dependant variables in neurofeedback: A proposal framework to identify cognitive processes and brain activity variables. Consciousness and Cognition, 2014, 26, 162-168.	0.8	11
200	A preliminary study on cognitive enhancer consumption behaviors and motives of French Medicine and Pharmacology students. European Review for Medical and Pharmacological Sciences, 2014, 18, 1875-8.	0.5	37
201	Self-reported major depressive symptoms at baseline impact abstinence prognosis in smoking cessation program. A one-year prospective study. Journal of Affective Disorders, 2013, 149, 418-421.	2.0	26
202	Fasting in mood disorders: neurobiology and effectiveness. A review of the literature. Psychiatry Research, 2013, 209, 253-258.	1.7	108
203	Nanopsychiatry—The potential role of nanotechnologies in the future of psychiatry: A systematic review. European Neuropsychopharmacology, 2013, 23, 1067-1071.	0.3	21
204	P.1.f.001 Drug repositioning of anti-inflammatory drugs in major psychiatric disorders. European Neuropsychopharmacology, 2013, 23, S185.	0.3	0
205	Troubles obsessionnels compulsifs résistants et antipsychotiquesÂ: données neurobiologiques et thérapeutiques actuelles. Annales Medico-Psychologiques, 2013, 171, 725-732.	0.2	0
206	Cognitive insight as an indicator of competence to consent to treatment in schizophrenia. Schizophrenia Research, 2013, 144, 118-121.	1.1	25
207	A further evaluation of decision-making under risk and under ambiguity in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 249-257.	1.8	53
208	Utilisation des antidépresseurs de seconde génération (SGA) dans la pratique quotidienne du médecinÂ: une synthèse à l'usage du clinicien. Annales Medico-Psychologiques, 2013, 171, 198-203.	0.2	0
209	Cyborg psychiatry to ensure agency and autonomy in mental disorders. A proposal for neuromodulation therapeutics. Frontiers in Human Neuroscience, 2013, 7, 463.	1.0	13
210	Physical Activity as a Protective Factor in Relapse Following Smoking Cessation in Participants with a Depressive Disorder. American Journal on Addictions, 2012, 21, 348-355.	1.3	13
211	Antipsychotic drugs: Pro-cancer or anti-cancer? A systematic review. Medical Hypotheses, 2012, 79, 38-42.	0.8	70
212	Treating patients with schizophrenia deficit with erythropoietin?. Psychiatry and Clinical Neurosciences, 2012, 66, 375-382.	1.0	15
213	The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome). International Psychogeriatrics, 2011, 23, 505-507.	0.6	19
214	Psychiatry Has to Take Care of Its Image On-Screen. primary care companion for CNS disorders, The, 2011, 13, .	0.2	1